Join the conversation

Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Loading...Loading...Loading...Loading...

Trending Tickers

NVTS logo
Top trending tickerNVTS
$13.54
10.98%
#1
Navitas selection by the U.S. Army to develop next-generation 10 kV silicon-carbide semiconductors under the ALATTIS program is driving attention, with traders viewing the award as validation of its technology and a potential defense-market opportunity. The reaction is mixed: some expect a continued rally or short squeeze, while others note that the prototype awards value and near-term revenue impact are unclear and have pointed to the initial pop fading.
BA logo
BA
$185.73
6.23%
#2
A 737 MAX flight-guidance software glitch has drawn FAA scrutiny and delayed MAX 10 certification, weighing on shares. Traders are split between viewing the issue as a fixable, previously disclosed problem and seeing it as another sign of Boeings quality and execution challenges; many dip buyers call the selloff excessive.
KOD logo
KOD
$88.13
172.43%
#3
Kodiaks Phase 3 DAYBREAK results in wet AMD are driving attention: both Zenkuda and tabirafusp-ted met primary goals, with Zenkuda showing potential for longer intervals between injections, and the company plans an FDA filing for Zenkuda. Traders are celebrating the sharp rally and possible short squeeze, while others warn that the move may be overextended and raise concerns about cash needs and potential dilution.
RDDT logo
RDDT
$143.89
3.97%
#4
RDDT is under pressure amid trader concerns that Googles publisher-payment pilot could weaken Reddits bargaining position or reduce the likelihood of a favorable AI data-licensing renewal; uncertainty around the separate Anthropic case also features in the discussion. Bears focus on deal risk and insider selling, while bulls argue Reddits user growth and data value still support the business.
CLF logo
CLF
$11.23
7.80%
#5
A proposed Iowa steel project backed by federal financing is weighing on Cleveland-Cliffs shares, as traders worry it could add future competition and question whether it will be built. Some argue the project is years away and faces execution hurdles, while separate concerns about production cuts and layoffs at Hamilton add to the bearish sentiment.
ACHR logo
ACHR
$5.24
6.60%
#6
ACHR is under pressure amid traders concerns about delays in Midnights transition testing and manufacturing milestones, with skeptics questioning execution and the path to revenue. Bulls point to the No Roads flight tour and Boeing-related defense and autonomy assets as signs of progress, leaving the discussion divided between near-term certification doubts and the longer-term business case.
NU logo
NU
$12.35
9.16%
#7
Reported talks to acquire UK digital bank Monzo are driving attention, with traders worried the costly deal could require dilution and pressure NUs shares. Others see the potential acquisition as a long-term route into the UK and Europe, though the discussions remain unconfirmed.
APLD logo
APLD
$24.74
5.75%
#8
A sustained selloff ahead of fiscal Q1 results has traders focused on whether Applied Digital can show progress bringing its AI data-center capacity online and converting its lease backlog into revenue. Bulls are buying the dip and looking for execution updates, while bears cite financing and dilution concerns, limited company communication, and uncertainty about the earnings reaction.
HBAR logo
HBAR
$0.1248
31.69%
#9
HBARs sharp, high-volume rally is being linked by traders to enterprise-AI developments, including an IBM Cloud identity integration and Hedera council members joining NVIDIAs Open Agent Safety Platform. Some traders instead attribute the move to momentum, a short squeeze, or crypto rotation, while others warn of profit-taking.
OCUL logo
OCUL
$7.75
19.69%
#10
Positive late-stage wet AMD results from Kodiak Sciences have intensified concerns about competition for Oculars AXPAXLI and coincided with a sharp selloff in OCUL. Traders are divided: some see the competitor data as raising the bar, while others argue the reaction is overdone and point to AXPAXLIs durability claims and planned FDA filing.

About Stocktwits

With over 10 million users, Stocktwits helps you tap into the real-time sentiment and trending insights across stocks, ETFs, and crypto.